Case Report Open Access
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. May 16, 2021; 9(14): 3478-3486
Published online May 16, 2021. doi: 10.12998/wjcc.v9.i14.3478
Paget’s disease of bone: Report of 11 cases
Xin-Yu Miao, Xian-Ling Wang, Zhao-Hui Lyu, Jian-Ming Ba, Yu Pei, Jing-Tao Dou, Wei-Jun Gu, Jin Du, Qing-Hua Guo, Kang Chen, Yi-Ming Mu
Xin-Yu Miao, Xian-Ling Wang, Zhao-Hui Lyu, Jian-Ming Ba, Yu Pei, Jing-Tao Dou, Wei-Jun Gu, Jin Du, Qing-Hua Guo, Kang Chen, Yi-Ming Mu, Department of Endocrinology, The First Medical Center, Chinese PLA General Hospital, Beijing 100853, China
Xin-Yu Miao, Department of Endocrinology, The Second Medical Center & National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing 100853, China
ORCID number: Xin-Yu Miao (0000-0002-3566-9412); Xian-Ling Wang (0000-0001-7350-4101); Zhao-Hui Lyu (0000-0003-1029-2126); Jian-Ming Ba (0000-0002-8748-5041); Yu Pei (0000-0001-6685-9916); Jing-Tao Dou (0000-0003-0375-6527); Wei-Jun Gu (0000-0001-8690-645X); Jin Du (0000-0001-6299-2306); Qing-Hua Guo (0000-0003-0267-2794); Kang Chen (0000-0002-6305-0908); Yi-Ming Mu (0000-0002-3344-3540).
Author contributions: Miao XY, Wang XL, and Pei Y prepared and collected the case data; Mu YM, Lyu ZH, Ba JM, Dou JT, Gu WJ, Du J, Guo QH, and Chen K analyzed the diagnosis and treatment of the case, and summarized the experience of diagnosis and treatment; Miao XY and Wang XL reviewed the literature and was responsible for drafting the manuscript; all authors gave final approval for the version to be submitted.
Supported by Special Scientific Research Project of Military Healthcare, No. 19BJZ29; Beijing Haidian District Health Development Research and Cultivation Program, No. HP-2021-03-80303.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare no conflicts of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Corresponding author: Xian-Ling Wang, MD, PhD, Chief Doctor, Department of Endocrinology, The First Medical Center, Chinese PLA General Hospital, No. 28 Fuxing Road, Beijing 100853, China.
Received: December 30, 2020
Peer-review started: December 30, 2020
First decision: January 24, 2021
Revised: February 2, 2021
Accepted: March 3, 2021
Article in press: March 3, 2021
Published online: May 16, 2021


Paget’s disease of bone (PDB) is a rare metabolic bone disease in China and is characterized by increased bone resorption and disorganized bone formation. The main clinical symptoms of PDB are focal or multiple bone pain and deformity with high disability. The disease has high missed diagnosis and misdiagnosis rates. This report summarizes the clinical manifestations, imaging and pathological features, and treatments of 11 patients with PDB at our hospital from 1993 to 2020 in order to improve the recognition and prognosis of PDB.


There were eight male and three female patients whose average age was 48.7 ± 11.0 years with a PDB course of 1-16 years. Nine patients had bone pain and bone deformities in different parts of the body, the majority of which involved the long bones. Laboratory examinations revealed elevated serum alkaline phosphatase (ALP) in all patients with an average of 618 ± 460 IU/L (normal range 0-130 IU/L), and serum calcium and phosphorus levels were in the normal range. Imageology showed that osteolysis was usually combined with osteosclerosis and/or bone deformities in single or multiple bones. 99mTc-methylene diphosphonate bone scintigraphy revealed increased radionuclide uptake in the bone lesions. Six patients underwent bone tissue biopsy, and the typical pathological changes were a mosaic structure of the bone trabeculae with irregularly arranged cement lines and multinuclear osteoclasts. Ten of the 11 patients were effectively treated with bisphosphonates.


Early diagnosis of the rare disease PDB can be made through elevated ALP levels and typical presentations on bone X-ray and from bone tissue biopsy.

Key Words: Paget’s disease of bone, Metabolic bone diseases, Chinese, Case report

Core Tip: Paget’s disease of bone (PDB) is a rare metabolic bone disease in China that has high missed diagnosis and misdiagnosis rates. We retrospectively summarize the clinical data of 11 patients with a diagnosis of PDB to provide additional clinical evidence for the disease. We found that PDB presented with a predisposition toward the older male population, and the main clinical symptoms were bone pain, deformity, and a high risk of disability. Early identification of PDB can be made through elevated alkaline phosphatase levels and typical presentations on bone X-ray and from bone tissue biopsy. Bisphosphonates are the first choice to improve the symptoms and prognosis.


Paget’s disease of bone (PDB), also known as osteitis deformans, was first discovered by the British surgeon James Paget in 1876[1]. PDB is a metabolic bone disease that presents with hyperactive bone remodeling and high-speed trabecular osteolysis leading to decreased bone quality and mechanical strength[2]. The chronic bone damage caused by PDB can be monostotic or polyostotic, and almost any bone can be affected, but the pelvis, spine, femur, tibia, skull, humerus, and scapula are involved more frequently. The common clinical manifestations are an abnormal bone structure, such as localized bone hypertrophy, and osteoporosis, leading to bone pain, bone deformity, and fracture. Significant regional and ethnic differences are observed in PDB patients. The prevalence of PDB is lower in Asian countries than in Western countries[3]. Due to its diverse clinical presentations and rarity in China, patients with PDB are often admitted to different departments and are prone to missed diagnosis or misdiagnosis; therefore, we retrospectively summarize the clinical data of 11 patients with a diagnosis of PDB from 1993 to 2020 at our hospital to provide more clinical evidence for the disease.

Chief complaints

Eleven patients (eight males and three females) with a diagnosis of PDB were enrolled. The average age was 48.7 ± 11.0 years, and the disease duration was 1-16 years. The chief complaints of the patients are shown in Table 1. Nine of the eleven patients had bone pain, and seven of the eleven had bone deformities. Two patients were admitted to the hospital because of a painless bony mass in the jaw.

Table 1 Clinicopathological data of 11 patients with Paget’s disease of bone.

Age (yr)
Chief complaints
X-ray findings
Bone scintigraphy findings
Pathology findings
1Male34Painless mass on right mandibleAn area of high-density bone sclerosis was seen on the right mandible measuring 2.5 cm × 2.5 cm × 2 cmNAMandibular mass resectionAbnormal bone hyperplasia accompanied by fibrous hyperplasia400
2Male46Right hip joint pain and outward deformity of the right lower limbLow density in the right femoral head was observed, with sparse patchy cystic areas. The articular surface was fuzzy with a narrowed joint spaceNALesion removal from the right hip jointMosaic appearance in bone trabeculae resulting from irregular cement lines505
3Male60Systematic bone pain with right humerus fractureThe diploic structure of the cranial bones was unclear. Bilateral femoral shafts were enlarged and deformed, with periosteal hyperplasia and ossification; the marrow cavity was irregular, and patchy, low-density areas were observed in cortical boneSymmetrical, increased radionuclide uptake in the skull, bilateral ribs, clavicles, humeri, tibiae and femursNANA1671
4Male65Bone pain and deformity of the left lower limbThe middle part of the left femur was bent, the bone cortex was thickened, and there were patches of low-density areas in the bone marrow cavityNANANA277
5Female48Left lower limb pain for 16 yr, with deformity for 14 yrThe cortex of the left femur was thickened, with the marrow cavity narrowed, and a sabre-like deformation was detected in the left femurNANANA248
6Male47Constant pain in the right hipMultiple cystic, low-density areas in the right ilium, ischia, and pubisAbnormal, increased radionuclide uptake in the skull, spine and pelvisCT-guided percutaneous biopsy of the right iliac boneObvious proliferation of localized matrix fibers in the bone paratrabecular area, with osteoclasts and osteoblasts aggregated457
7Female66Lumbar and lower limb pain with kyphosisThe pelvic bones and bilateral upper femur had multiple radiolucent spaces, with uneven bone densitySystemic osteolytic changesPercutaneous biopsy of the left upper femurIrregular trabeculae and hyperplasia of bone fibrous connective tissue817
8Male42Pain, deformity and limited mobility in the left kneeDiffuse bone lesions in the left femur, tibia, and fibula with thickened bone cortex and uneven density in the marrow cavity were observedDiffuse, increased radionuclide uptake in the skull, left scapula, right fifth anterior rib, and right hemipelvis and limb bonesNANA1212
9Male39Pain and deformity of the left calfThe anterior arch of the left tibia was deformed and demonstrated disordered boneNAPercutaneous biopsy of the left tibiaHyperplastic and disordered lamellar bone tissue of the left tibia and irregular broad trabeculae with fibrous vascular tissue203
10Male37Left hip pain for 16 yr, with claudication for 1 yrMultiple uneven density bone lesions were observed in the middle and upper right humeri, left femur, and pelvis, showing multiple cystic radiolucent spaces, a thickened bone cortex, a narrowed marrow cavity, and a sabre-like deformation of the femurIncreased radionuclide uptake in the 11 thoracic vertebrae, pelvis, right humerus, and left femurNANA312
11Female52Right maxillary massExpansion of the sphenoid bone, bilateral maxillae, cheekbones, temporal bones, and occipital bone was observed, and the diploic structure of the cranial bones was unclearNARight maxillary mass resectionMosaic appearance caused by randomly arranged cement lines and multinuclear osteoclasts699
History of present illness

The features of bone pain were constant and worsened at rest. Bone deformities included localized bone expansion and bending of the long bones during weight-bearing. Four patients had monostotic bone deformation, and seven patients had polyostotic bone deformation. The long bones (8/11) and hip (5/11) were the most affected bones. One patient (case 3) had a fracture of the right humerus. The 11 patients were admitted to departments of endocrinology, orthopedics, stomatology, and rheumatology separately. Before admission to our hospital, four patients (cases 5, 7, 9, and 10) were misdiagnosed with fibrous dysplasia of bone, bone metastases, bone tumours, and osteoarthritis, respectively. Patients 1 and 11 were admitted to the Department of Stomatology for jawbone lesions.

History of past illness

There was no history of essential hypertension, diabetes mellitus, or relevant cerebrovascular disease. The patients also had no history of confirmed malignant tumours.

Personal and family history

Four patients had a smoking history. Family members of the patients did not have metabolic bone diseases or bone deformities.

Physical examination

Body temperature, blood pressure, respiratory rate, and heart rate were all in the normal range on admission. There were no other obvious symptoms except bone deformities (localized bone expansion and bending of long bones) and limited mobility of the hip or knee joints in seven of eleven patients.

Laboratory examinations

Laboratory examinations revealed a significant increase in serum alkaline phosphatase (ALP) level, which was 618 ± 460 IU/L (normal range, 0-130 IU/L), while serum calcium 2.37 ± 0.16 mmol/L (2.09-2.54 mmol/L) and phosphorus 1.17 ± 0.21 mmol/L (0.89-1.60 mmol/L) were in the normal range.

Imaging examinations

The X-ray examination showed bone resorption, destruction, and sclerosis at different levels and ranges, characterized by an uneven bone density, cystic, light-transmitting areas and bone expansion and deformities (Figure 1A-D); 99mTc-methylene diphosphonate (MDP) bone scintigraphy indicated increased radionuclide uptake in the bone lesions (Figure 1E).

Figure 1
Figure 1 Imaging changes in patients with Paget’s disease of bone. A: Radiograph of case 8 showing bone lesions in the skull and cranial plate and a slightly thickened, localized high-density “cotton ball” appearance (arrowhead); B: X-ray of the lower limbs from case 8 showing diffuse bone lesions in the left femur, tibia, and fibula, a thickened bone cortex, uneven density in the marrow cavity, and expanded femur and tibia metaphyses; C: X-ray of the hip from case 10 showing multiple cystic radiolucent spaces in the pelvic bones; D: Radiograph of the left femur from case 10 showing a thickened bone cortex, narrowed marrow cavity, and sabre-like deformation of the femur; E: Technetium-99 conjugated with methylene diphosphonate bone scans from case 8 showing increased uptake of radionuclide in the skull, left scapula, right fifth anterior rib, and right hemipelvis and limb bones.

The diagnosis of PDB was based on the findings from bone biopsy or postoperative pathology. Pathological changes included the formation of irregular, broad bone trabeculae and fibrous vascular tissue, a mosaic structure of the bone trabeculae with irregular cement lines and multinuclear osteoclasts (Figure 2).

Figure 2
Figure 2 Histopathological features of Paget’s disease of bone. A: Biopsy specimen from case 9 showing irregular broad bone trabeculae (arrowhead 1) and fibrous vascular tissue (arrowhead 2); B: Pathological tissue from case 11 showing a mosaic appearance with irregularly arranged cement lines (arrowhead 3) and multinuclear osteoclasts (arrowhead 4) (hematoxylin-eosin staining, magnification × 200).

In the absence of pathology, the diagnosis depended on clinical manifestations, including bone pain, bone deformity and/or pathological fractures, X-rays (localized or multiple-bone osteolysis and sclerosis accompanied by bone deformity or fracture), 99mTc-MDP bone scan imaging (multiple abnormal radionuclide concentrations), and a significantly elevated serum ALP level[4].


Two patients were treated with three cycles of 200 mg etidronate sodium twice a day orally for 2 wk and withdrawal for 11 wk; two patients were treated with 10 mg alendronate once a day orally for 7 mo; three patients were treated with an intravenous injection of 15 mg pamidronate bisphosphonate every week for 7 wk; and three patients were treated with an intravenous injection of 5 mg zoledronate per year for 2 or 3 years (Table 2). Calcium (600 mg elemental calcium) and vitamin D (vitamin D 1000 IU/d or calcitriol 0.25 μg/d) were administered simultaneously. Cases 1, 2, and 11 underwent bone lesion surgery.

Table 2 Medical treatment and follow-up for the 11 patients with Paget’s disease of bone.

Medical treatment
ALP (posttreatment IU/L)
1NA1 yrNo symptomNA
2Three cycles of etidronate sodium 200 mg administered twice a day orally for 2 wk and withdrawn for 11 wk10 yrBone pain relieved; mobility of the affected limb improved after surgery311
3Pamidronate bisphosphonate 15 mg/week intravenous injection for 7 wk3 moBone pain relieved1398
4Three cycles of etidronate sodium 200 mg administered twice a day orally for 2 wk and withdrawn for 11 wk19 yrBone pain relieved212
5Alendronate 10 mg once a day orally for 7 mo15 yrBone pain relieved158
6Pamidronate bisphosphonate 15 mg/week intravenous injection for 7 wk3 yrBone pain relieved245
7Alendronate 10 mg once a day orally for 7 mo3 yrBone pain relieved752
8Zoledronate 5 mg per year intravenous injection for 3 yr5 yrBone pain relieved977
9Zoledronate 5 mg per year intravenous injection for 3 yr3 yrBone pain relieved60
10Zoledronate 5 mg per year intravenous injection for 2 yr2 yrBone pain relieved52
11Pamidronate bisphosphonate 15 mg/week intravenous injection for 7 wk1 yrNo symptom405

Bone pain was relieved after bisphosphonate treatment with good tolerance. The mobility of the affected limb for case 2 improved after surgery. Mean serum ALP level decreased significantly to 457 ± 445 IU/L (bP < 0.01). Serum calcium and phosphorus levels did not change significantly compared to the levels before treatment.


PDB is a chronic metabolic bone disease with a predisposition for older people, and more men than women tend to develop the disease. The disease is prone to missed diagnosis or misdiagnosis due to its diverse clinical manifestations and is usually asymptomatic during the early phase[5]. PDB is rare in China, and few reports have described it in individuals of Chinese ancestry. Clinicians should work to improve their recognition of PDB to reduce the disease course and disability. In this report, only 11 patients were diagnosed with PDB over 27 years at our hospital, including eight males and three females, with an average age of 48.7 ± 11.0 years. We summarize the clinical and pathological features of the cases to provide more evidence for the disease.

The etiology of PDB remains unclear, but some studies suggest that several genes involved in the differentiation or function of osteoclasts[6-9] and environmental factors, such as viral infection, particularly measles, animal contact, pesticides, and tobacco smoke, together play important roles in its pathogenesis[10]. Furthermore, rapidly increased bone resorption accompanied by abnormal new bone formation is a substantial PDB pathological characteristic. The number of enlarged and multinucleated osteoclasts increases dramatically during the early stage of the disease, and abnormal osteoclasts accumulate in the Haversian canal, trabeculae, and endosteal surfaces. Then, bony destruction by osteoclasts stimulates marrow fibrosis, increases the vascularity of the bone, and increases the activity of osteoblasts. Finally, new bone is formed and absorbed repeatedly as the disease progresses, which leads to a disorganized architecture and the production of woven bone. A mosaic appearance can be seen in which there is an admixture of woven and lamellar bone[11]. In this study, the bone biopsy pathological findings showed typical changes in PDB, such as a mosaic structure in the bone trabeculae with irregular cement lines and multinuclear osteoclasts (Figure 2).

The clinical manifestations of PDB are nonspecific, and bone pain, the most common symptom, is constant and tends to worsen at night and upon weight bearing[12]. Other presentations include fractures, osteoarthritis, bone deformities, spinal canal stenosis, and paraplegia. The skull can be affected, which can lead to an enlarged head, and compression of nerves and brain tissues may cause headache and hearing loss[13]. The majority of patients in this report had bone pain and deformities, but none had headache or hearing loss. The bone lesions mainly involved the pelvis (5/11) and femur (7/11), followed by the spine, tibia, humerus, skull, ribs, clavicle, and scapula. Jawbones were affected in two cases.

The diagnosis of PDB is usually made by X-ray and elevated serum ALP levels, particularly in asymptomatic patients[14,15]. Common X-ray features include localized osteoporosis distributed along the trabecular bone in a wedge shape. A long bone absorption zone, such as in a “V”-shape, is typical during the early stage of the disease. Bone deformities, including bone cortex expansion, thickening, and deformation, are common. The edges of the cortical bone and trabecular bone in the lesion are rough and villi-like, and patchy frosted glass-like high-density foci are observed. Fractures follow this stage. In this study, the X-rays of case 8 revealed localized frosted glass-like high-density lesions in the skull (Figure 1A). The X-rays of case 10 showed multiple cystic translucent areas of the pelvis and deformation of the left femur into a “sabre shape” (Figure 1B and C). After PDB is visualized on X-ray, radionuclide bone scintigraphy is used to determine any additional lesions. The characteristic features on radionuclide bone scintigraphy are osteolysis during the initial stage, followed by osteogenesis and osteosclerosis. Marked increased radionuclide uptake can be seen during the osteolysis and osteogenesis stages of the disease, and low uptake is seen in sclerotic (“burned out”) lesions[16]. The bone scintigraphy of case 8 in this report showed increased radionuclide uptake in the skull, scapula, ribs, pelvis, and limbs (Figure 1D).

PDB is prone to misdiagnosis because of it various nonspecific clinical manifestations and rarity in China. Four patients in this report were misdiagnosed with fibrous dysplasia of bone, bone metastases, bone tumours, or osteoarthritis separately, and one was misdiagnosed with hyperparathyroidism on admission. PDB can be easily confused with bone tumours, bone metastases, fibrous dysplasia of bone, and hyperparathyroidism in clinical practice. Bone tumours (giant cell tumours, bone hemangiomas, or osteosarcomas) or bone metastases are similar to PDB[17,18], in which the most common symptom is bone pain. X-rays show osteolytic destruction, and bone scintigraphy shows increased radionuclide uptake with an elevated serum ALP level. However, the most common sites of involvement in patients with PDB are the pelvis and femur, which are characterized by broad trabeculae and thickened cortical bone on X-rays, whereas patients with bone tumours or bone metastases are often accompanied by systemic symptoms of consumption, such as fatigue and weight loss. Moreover, their blood ALP levels do not match those of patients with bone lesions. The osteolytic changes in PDB are prone to be confused with fibrous dysplasia of bone. The characteristic X-ray features of patients with fibrous dysplasia of bone are frosted glass-like, loofah-like, and cystic swelling changes and bone cortex thinning at lesion sites[19], with serum ALP levels in the normal range or slightly elevated but lower than those of patients with PDB. Histology of the affected bone is helpful in the diagnosis. Identifying PDB with hyperparathyroidism depends on medical history, calcium, phosphorus, and parathyroid hormone examinations as well as ultrasound of the parathyroid and bone X-rays[20].

The treatment for PDB is aimed at suppressing osteoclast activity and reducing bone turnover from a pathophysiological standpoint. Bisphosphonates suppress increased bone resorption and decrease serum ALP and are an ideal choice for treating PDB[21]. Multiple bisphosphonates have been approved by the United States Food and Drug Administration to treat PDB, among which zoledronic acid is most likely to relieve bone pain[4]. Studies have demonstrated that zoledronic acid is superior to other bisphosphonates for normalizing ALP levels and suppressing bone turnover markers[22]. In this report, all patients treated with a bisphosphonate responded, and their ALP levels decreased after short-term therapy. In addition, the clinical guidelines[23] suggest that total hip or knee replacement is recommended for PDB patients accompanied by osteoarthritis for whom medical treatment is refractory. The patient in case 2 underwent hip debridement surgery, and his limb activity improved.

Approximately 10% of patients with PDB develop malignant degeneration, primarily older men. Osteosarcoma is the most common malignant change, followed by fibrosarcoma and lymphosarcoma[24]. The main clinical symptoms of malignant PDB are an aggravation of constant pain, soft tissue swelling, and the occurrence of new lumps. Malignant degeneration is indicated by extended lesions, worm-eaten cortical bone destruction, and periosteal reactions. In this study, no malignant changes were detected, but long-term follow-up should be performed.


PDB is rare in China, but it is necessary to improve recognition of the disease with early diagnosis and treatment due to its high rate of disability. We report 11 PDB patients and summarize their clinical manifestations, laboratory and imaging examinations, pathological bone lesion characteristics, and main treatment methods, which may provide more evidence for the early identification of PDB.


We thank Li B at the Department of Pathology, The First Medical Center, Chinese PLA General Hospital for pathological data collection.


Manuscript source: Unsolicited manuscript

Specialty type: Medicine, research and experimental

Country/Territory of origin: China

Peer-review report’s scientific quality classification

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

P-Reviewer: Ma L S-Editor: Fan JR L-Editor: Wang TQ P-Editor: Ma YJ

1.  Ralston SH. Clinical practice. Paget's disease of bone. N Engl J Med. 2013;368:644-650.  [PubMed]  [DOI]
2.  Hsu E. Paget's disease of bone: updates for clinicians. Curr Opin Endocrinol Diabetes Obes. 2019;26:329-334.  [PubMed]  [DOI]
3.  Griz L, Fontan D, Mesquita P, Lazaretti-Castro M, Borba VZ, Borges JL, Fontenele T, Maia J, Bandeira F;  Brazilian Society of Endocrinology and Metabolism. Diagnosis and management of Paget's disease of bone. Arq Bras Endocrinol Metabol. 2014;58:587-599.  [PubMed]  [DOI]
4.  Ralston SH, Corral-Gudino L, Cooper C, Francis RM, Fraser WD, Gennari L, Guañabens N, Javaid MK, Layfield R, O'Neill TW, Russell RGG, Stone MD, Simpson K, Wilkinson D, Wills R, Zillikens MC, Tuck SP. Diagnosis and Management of Paget's Disease of Bone in Adults: A Clinical Guideline. J Bone Miner Res. 2019;34:579-604.  [PubMed]  [DOI]
5.  Malik AR, Lone NA, Rather HA, Jan VM, Malik JA, Khan KA, Jalal S. Asymptomatic Paget's disease of bone presenting with complete atrioventricular block. Chin Med J (Engl). 2008;121:2357-2359.  [PubMed]  [DOI]
6.  Gu JM, Zhang ZL, Zhang H, Hu WW, Wang C, Yue H, Ke YH, He JW, Hu YQ, Li M, Liu YJ, Fu WZ. Thirteen Chinese patients with sporadic Paget's disease of bone: clinical features, SQSTM1 mutation identification, and functional analysis. J Bone Miner Metab. 2012;30:525-533.  [PubMed]  [DOI]
7.  Goode A, Long JE, Shaw B, Ralston SH, Visconti MR, Gianfrancesco F, Esposito T, Gennari L, Merlotti D, Rendina D, Rea SL, Sultana M, Searle MS, Layfield R. Paget disease of bone-associated UBA domain mutations of SQSTM1 exert distinct effects on protein structure and function. Biochim Biophys Acta. 2014;1842:992-1000.  [PubMed]  [DOI]
8.  Qi X, Pang Q, Wang J, Zhao Z, Wang O, Xu L, Mao J, Jiang Y, Li M, Xing X, Yu W, Asan, Xia W. Familial Early-Onset Paget's Disease of Bone Associated with a Novel hnRNPA2B1 Mutation. Calcif Tissue Int. 2017;101:159-169.  [PubMed]  [DOI]
9.  Guay-Bélanger S, Picard S, Gagnon E, Morissette J, Siris ES, Orcel P, Brown JP, Michou L. Detection of SQSTM1/P392L post-zygotic mutations in Paget's disease of bone. Hum Genet. 2015;134:53-65.  [PubMed]  [DOI]
10.  Numan MS, Jean S, Dessay M, Gagnon E, Amiable N, Brown JP, Michou L. Gene-environment interactions in Paget's disease of bone. Joint Bone Spine. 2019;86:373-380.  [PubMed]  [DOI]
11.  Zimmermann EA, Köhne T, Bale HA, Panganiban B, Gludovatz B, Zustin J, Hahn M, Amling M, Ritchie RO, Busse B. Modifications to nano- and microstructural quality and the effects on mechanical integrity in Paget's disease of bone. J Bone Miner Res. 2015;30:264-273.  [PubMed]  [DOI]
12.  Bolland MJ, Cundy T. Paget's disease of bone: clinical review and update. J Clin Pathol. 2013;66:924-927.  [PubMed]  [DOI]
13.  Wang QY, Fu SJ, Ding N, Liu SY, Chen R, Wen ZX, Fu S, Sheng ZF, Ou YN. Clinical features, diagnosis and treatment of Paget's disease of bone in mainland China: A systematic review. Rev Endocr Metab Disord. 2020;21:645-655.  [PubMed]  [DOI]
14.  Singer FR, Bone HG 3rd, Hosking DJ, Lyles KW, Murad MH, Reid IR, Siris ES;  Endocrine Society. Paget's disease of bone: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99:4408-4422.  [PubMed]  [DOI]
15.  Bao CH, Zhang ZL. Diagnosis and treatment for 8 cases with Paget disease. Shanghai Yiyao. 2012;35:530-533.  [PubMed]  [DOI]
16.  Wang XL, Yang G, Lu JM, Dou JT, Mu YM, Meng JH, Pan CY, Shi HY. Clinical analysis of 7 patients with Paget’s disease of bone. Zhonghua Neifenmi Daixie Zazhi . 2008;24:412-414.  [PubMed]  [DOI]
17.  Du HQ, Zheng Y, Zhang M, He XF, Liu LY, Zhang ZL. Paget’s disease of bone misdiagnosed as hemangioma: report of one case. Zhonghua Neifenmi Daixie Zazhi. 2015;31:176-178.  [PubMed]  [DOI]
18.  Gezer NS, Balcı A, Özdoğan Ö, Özaksoy D. Paget's Disease Mimicking Bone Metastasis in a Patient with Neuroendocrine Tumor on 68Ga-DOTANOC PET/CT. J Belg Soc Radiol. 2016;100:66.  [PubMed]  [DOI]
19.  Lu CZ, Xiao WJ, Zhang ZL. The value of bone scintigraphy in diagnosis of fibrous dysplasia of bone. Zhonghua Guzhishusong He Gukuangyanjibing Zazhi. 2011;4:82-86.  [PubMed]  [DOI]
20.  Xu B, Yu J, Lu Y, Han B. Primary hyperparathyroidism presenting as a brown tumor in the mandible: a case report. BMC Endocr Disord. 2020;20:6.  [PubMed]  [DOI]
21.  Gennari L, Rendina D, Falchetti A, Merlotti D. Paget's Disease of Bone. Calcif Tissue Int. 2019;104:483-500.  [PubMed]  [DOI]
22.  Devogelaer JP, Geusens P, Daci E, Gielen E, Denhaerynck K, Macdonald K, Hermans C, Vancayzeele S, Abraham I, Boonen S. Remission over 3 years in patients with Paget disease of bone treated with a single intravenous infusion of 5 mg zoledronic acid. Calcif Tissue Int. 2014;94:311-318.  [PubMed]  [DOI]
23.  Paul Tuck S, Layfield R, Walker J, Mekkayil B, Francis R. Adult Paget's disease of bone: a review. Rheumatology (Oxford). 2017;56:2050-2059.  [PubMed]  [DOI]
24.  Rendina D, De Filippo G, Ralston SH, Merlotti D, Gianfrancesco F, Esposito T, Muscariello R, Nuti R, Strazzullo P, Gennari L. Clinical characteristics and evolution of giant cell tumor occurring in Paget's disease of bone. J Bone Miner Res. 2015;30:257-263.  [PubMed]  [DOI]